Growth Metrics

Alnylam Pharmaceuticals (ALNY) Operating Income (2009 - 2026)

Alnylam Pharmaceuticals posted quarterly Operating Income of $268.6 million for Q1 2026, up 1386.07% year-on-year from $18.1 million in Q1 2025, and up 103.95% on a QoQ basis from $131.7 million in Q4 2025.

Alnylam Pharmaceuticals (ALNY) has 18 years of Operating Income data on file, last reported at $268.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Operating Income rose 1386.07% year-over-year to $268.6 million; the trailing twelve-month figure through Mar 2026 stood at $752.1 million (up 751.92% YoY), and the FY2025 full-year result was $501.6 million, up 383.56% from the prior year.
  • Operating Income for Q1 2026 stood at $268.6 million, up from $131.7 million in the prior quarter.
  • Across five years, Operating Income topped out at $368.0 million in Q3 2025 and bottomed at -$258.0 million in Q3 2022.
  • The 5-year median for Operating Income is -$76.9 million (2024), against an average of -$27.9 million.
  • The widest annual swing landed in 2024, when Operating Income tumbled 135.96%; it then soared 1386.07% in 2026.
  • A 5-year view of Operating Income shows it stood at -$188.6 million in 2022, then surged by 38.28% to -$116.4 million in 2023, then grew by 9.66% to -$105.2 million in 2024, then jumped by 225.26% to $131.7 million in 2025, then soared by 103.95% to $268.6 million in 2026.
  • The last three Operating Income figures came in at $268.6 million (Q1 2026), $131.7 million (Q4 2025), and $368.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -2.97 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -19.70 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -15.76 Mn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 1.14 Bn
7 Evaxion A 62.56 Bn 62.54 Bn - -3.82 Mn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 642.90 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 268.64 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn - -445.22 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 268.64 Mn
Dec 31, 2025 131.72 Mn
Sep 30, 2025 367.98 Mn
Jun 30, 2025 -16.20 Mn
Mar 31, 2025 18.08 Mn
Dec 31, 2024 -105.16 Mn
Sep 30, 2024 -76.91 Mn
Jun 30, 2024 48.61 Mn
Mar 31, 2024 -43.44 Mn
Dec 31, 2023 -116.40 Mn
Sep 30, 2023 213.87 Mn
Jun 30, 2023 -229.83 Mn
Mar 31, 2023 -149.81 Mn
Dec 31, 2022 -188.61 Mn
Sep 30, 2022 -258.04 Mn
Jun 30, 2022 -191.69 Mn
Mar 31, 2022 -146.73 Mn
Dec 31, 2021 -194.56 Mn
Sep 30, 2021 -181.68 Mn
Jun 30, 2021 -146.16 Mn
Mar 31, 2021 -186.25 Mn
Dec 31, 2020 -194.22 Mn
Sep 30, 2020 -225.20 Mn
Jun 30, 2020 -198.86 Mn
Mar 31, 2020 -210.16 Mn
Dec 31, 2019 -298.07 Mn
Sep 30, 2019 -216.30 Mn
Jun 30, 2019 -236.27 Mn
Mar 31, 2019 -188.79 Mn
Dec 31, 2018 -220.36 Mn
Sep 30, 2018 -254.56 Mn
Jun 30, 2018 -192.35 Mn
Mar 31, 2018 -147.41 Mn
Dec 31, 2017 -147.30 Mn
Sep 30, 2017 -125.80 Mn
Jun 30, 2017 -120.47 Mn
Mar 31, 2017 -106.51 Mn
Dec 31, 2016 -115.43 Mn
Sep 30, 2016 -106.68 Mn
Jun 30, 2016 -92.45 Mn
Mar 31, 2016 -110.03 Mn
Dec 31, 2015 -92.51 Mn
Sep 30, 2015 -78.33 Mn
Jun 30, 2015 -72.94 Mn
Mar 31, 2015 -52.22 Mn
Dec 31, 2014 -45.71 Mn
Sep 30, 2014 -45.20 Mn
Jun 30, 2014 -45.01 Mn
Mar 31, 2014 -269.06 Mn
Dec 31, 2013 -29.59 Mn
Sep 30, 2013 -32.23 Mn
Jun 30, 2013 -21.31 Mn
Mar 31, 2013 -9.80 Mn
Dec 31, 2012 -88.35 Mn
Sep 30, 2012 -18.15 Mn
Jun 30, 2012 -12.07 Mn
Mar 31, 2012 -10.89 Mn
Dec 31, 2011 -13.59 Mn
Sep 30, 2011 -12.44 Mn
Jun 30, 2011 -13.12 Mn
Mar 31, 2011 -15.68 Mn
Dec 31, 2010 -12.41 Mn
Sep 30, 2010 -8.73 Mn
Jun 30, 2010 -11.63 Mn
Mar 31, 2010 -11.31 Mn
Dec 31, 2009 -8.07 Mn
Sep 30, 2009 -9.65 Mn
Jun 30, 2009 -22.41 Mn